Company profile: BioXcel Therapeutics
1.1 - Company Overview
Company description
- Provider of AI-driven drug re-innovation and therapeutics, including IGALMI, an FDA-approved sublingual film for acute agitation in adults with schizophrenia or bipolar I/II; BXCL501, an investigational dissolving dexmedetomidine film for agitation related to Alzheimer’s dementia and bipolar or schizophrenia; BXCL701, an oral innate immune activator under investigation for aggressive prostate, pancreatic, and other solid and liquid tumors; plus an Expanded Access Program.
Products and services
- AI-based Drug Re-innovation: Platform that expedites discovery and development of new indications for existing drugs and late-stage candidates using artificial intelligence to accelerate program advancement, AI-driven
- IGALMI: Sublingual film for acute treatment of agitation in adults with schizophrenia or bipolar I or II disorder, formulated for placement under the tongue, FDA-approved
- BXCL501: Orally dissolving film formulation of dexmedetomidine for treating agitation related to Alzheimer’s dementia and bipolar disorders or schizophrenia, pursued as a novel film-based therapeutic, investigational
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BioXcel Therapeutics
Anji Pharma
HQ: United States
Website
- Description: Provider of therapeutics targeting high-value, human genetics-validated targets, including ANJ900, a gut-targeted formulation of metformin for type 2 diabetes patients with advanced chronic kidney disease to lower glucose with reduced systemic exposure, and ANJ908 (Pradigastat), a DGAT1 inhibitor for chronic idiopathic constipation to increase bowel movement frequency and soften stool.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anji Pharma company profile →
Q BioMed
HQ: United States
Website
- Description: Provider of radiopharmaceutical and therapeutic candidates, including Strontium-89 Chloride Injection for relief of bone pain from skeletal metastases; Uttroside-B, a chemotherapeutic agent under development for liver cancer; QBM-001, a preclinical candidate targeting pediatric minimally verbal autism spectrum disorder; and MAN-01, a preclinical topical eyedrop for glaucoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Q BioMed company profile →
Sirtris Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development focused on discovering and developing proprietary, orally available small molecule drugs to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sirtris Pharmaceuticals company profile →
Cephalon
HQ: United States
Website
- Description: Provider of biopharmaceutical discovery, development, and commercialization of medications to improve quality of life worldwide. Founded in 1987, the company delivers first-in-class and best-in-class medicines across several therapeutic areas.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cephalon company profile →
FibroGen
HQ: United States
Website
- Description: Provider of novel therapeutics leveraging CTGF and HIF biology, including Roxadustat, an oral small molecule for anemia in CKD patients on or off dialysis; Pamrevlumab, a human monoclonal antibody in development for metastatic and locally advanced pancreatic cancer and DMD; and FG-3246, a first-in-class fully human ADC targeting CD46 for metastatic castration-resistant prostate cancer and other tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full FibroGen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BioXcel Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BioXcel Therapeutics
2.2 - Growth funds investing in similar companies to BioXcel Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BioXcel Therapeutics
4.2 - Public trading comparable groups for BioXcel Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →